Interim report Q3/2022: A broader role for ColdZyme adds potential for the future

Significant Significant events after the quarterevents duringthe quarter · To ensure · On October 31, the journal Respiratory Research published athe long-term study from the Medical University of Innsbruck, Austria, whichfinancing of shows that ColdZyme blocks the widespread and highlythe business, transmissible omicron variants BA.4 and BA.5 from adhering toin September and infecting human cells. According to the research group thatthe company conducted the study, this opens the possibility that ColdZymeraised about can be applied in the prevention of